STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Completed
- Bioequivalence
- Treatment A: Acalabrutinib tablet
- Treatment B: Acalabrutinib capsule
- Glendale, California
- +2 more
2021-06-01
Jun 1, 2021U
Recruiting
- Central Nervous System Lymphoma
- Acalabrutinib
- Isavuconazole
- Chapel Hill, North Carolina
- +1 more
2022-03-24
Mar 24, 2022U
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
2021-08-04
Aug 4, 2021W
Withdrawn
- Chronic Lymphocytic Leukemia
- CLL/SLL
- Acalabrutinib
- New York, New YorkWeill Cornell Medicine
2022-03-25
Mar 25, 2022U
Recruiting
- Diffuse Large B Cell Lymphoma
- R-CHOP
- R-CHOP + acalabrutinib
- Colchester, Essex, United Kingdom
- +2 more
2021-10-20
Oct 20, 2021D
Recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
- Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
2022-02-02
Feb 2, 2022D
Recruiting
- Central Nervous System Lymphoma
- +2 more
- Acalabrutinib
- Boston, Massachusetts
- +1 more
2022-01-05
Jan 5, 2022A
Active, not recruiting
- Mantle Cell Lymphoma (MCL)
- Acalabrutinib in combination with BR
- Acalabrutinib in combination with VR
- Louisville, Kentucky
- +14 more
2022-01-19
Jan 19, 2022U
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- R-CHOP chemotherapy
- Vancouver, British Columbia, Canada
- +3 more
2022-03-17
Mar 17, 2022W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
- Saint Louis, MissouriWashington University School of Medicine
2022-02-02
Feb 2, 2022S
Recruiting
- Diffuse Large B Cell Lymphoma
- Carboplatin
- +8 more
- Seattle, WashingtonSwedish Cancer Institute
2021-03-01
Mar 1, 2021A
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
- Bethesda, MarylandResearch Site
2022-01-19
Jan 19, 2022A
U
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Acalabrutinib
- Rituximab
- Rochester, New YorkUniversity of Rochester
2022-02-07
Feb 7, 2022W
Recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- Durvalumab
- Acalabrutinib
- Saint Louis, MissouriWashington University School of Medicine
2022-03-14
Mar 14, 2022F
Recruiting
- Recurrent Moderate-Severe Chronic Graft Versus Host Disease
- Hematopoietic and Lymphoid Cell Neoplasm
- Acalabrutinib
- Questionnaire Administration
- Tampa, Florida
- +3 more
2021-12-22
Dec 22, 2021S
Withdrawn
- Lymphoma
- Leukemia
- Acalabrutinib, tacrolimus, methotrexate
- (no location specified)
2022-02-20
Feb 20, 2022A
Completed
- Healthy Volunteers
- Acalabrutinib
- +2 more
- Tempe, ArizonaCelerion
2021-11-17
Nov 17, 2021C
Recruiting
- Autoimmune Hemolytic Anemia
- +3 more
- Acalabrutinib
- Duarte, CaliforniaCity of Hope Medical Center
2022-03-09
Mar 9, 2022M
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
- Houston, TexasM D Anderson Cancer Center
2021-11-18
Nov 18, 2021A
Completed
- Mantle Cell Lymphoma
- COVID-19
- Acalabrutinib Treatment A
- +3 more
- Berlin, GermanyResearch Site
2020-12-28
Dec 28, 2020J
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
- Acalabrutinib
- Los Angeles, California
- +2 more
2022-03-17
Mar 17, 2022F
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- Venetoclax
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022A
Completed
- Hepatic Impairment
- +2 more
- acalabrutinib
- Miami, Florida
- +2 more
2021-08-16
Aug 16, 2021A
Completed
- Healthy Volunteers
- Lincoln, NebraskaLaura Sterling, MD, MPH
2021-05-05
May 5, 2021